The European Union's counterpart to the FDA, the European Medicines Agency, is creating a policy that would require drugmakers to publish some clinical trial data for drugs submitted for approval. Stakeholders in the U.K. are set to meet this month to further discuss the challenges of data openness.

Related Summaries